Title: Results of a Phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
- Date and time: October 20, 2018, 15:00
- Presentation number: 1049PD
- Session: Poster Discussion session – Head and neck
- Presenter: Jérôme Fayette, Medical Oncologist at the Centre Léon Bérard Lyon, France
- Location: Hall B3 – Room 23, ICM München, Munich, Germany
- See the poster
A KOL call will be held on Monday, October 22, 4pm CEST (10 am EDT). Dial-in numbers:
- France and International: +33 (0)1 72 72 74 03
- US: +1 646 722 4916
- PIN code: 69616804#
Replay of the conference call.
Title: Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with Durvalumab plus Monalizumab (anti-NKG2A)
- Date & time: October 20, 2018, 12:30
- Presentation number: 1194P
- Session: Poster Display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research (ID 259)
- Presenter: Jennifer R. Diamond, Associate Professor, Division of Medical Oncology at the Colorado University, Denver, US
- Location: Hall A3, Poster Area Networking Hub, ICM München, Munich, Germany
Title: Changes in the innate immune system as early events in cancer
- Date & time: October 22, 2018, 15:05 – 15:25
- Session: Special Symposium Early detection of cancer using minimally invasive biomarkers
- Presenter: Eric Vivier, Chief Scientific Officer of Innate Pharma, Marseille, France
- Location: Hall A1 – Room 17, ICM München, Munich, Germany
Date